Sorry, you need to enable JavaScript to visit this website.

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign-up to receive all GMG announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts
Title
Grant Type
Focus Area
Country
Application Due Date
Research in Ulcerative Colitis (UC) 2024
Release Date:
Review Process: Expert Review Panel
Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Research Oncology USA
BCMA-Directed Bispecific Antibody Treatment in Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Translation: Japanese (link)
Education Oncology Japan
Research on MBL producing Enterobacterales and/or Stenotrophomonas maltophilia
Release Date:
Review Process: Pfizer Internal
Research Hospital Austria, Brazil, China, France, Germany, Greece, India, Italy, Mexico, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom
Increase Awareness & Understanding of Emerging Hemophilia Treatment Options (Global excluding United States)
Release Date:
Review Process: Pfizer Internal
Education Rare Disease All
Optimal management of patients with prostate cancer receiving androgen deprivation therapy (ADT)
Release Date:
Partner: Sumitomo Pharma
Review Process: Pfizer Internal
Education Oncology USA
Title
Grant Type
Focus Area
Country
Application Due Date
Quality Improvement initiatives optimizing AF and VTE management in Canada
Release Date:
Review Process:
Improving the Management of Patients with Uncontrolled Acromegaly (International Developed Markets)
Release Date:
Review Process:
Pfizer and the National Kidney Foundation: Improving Immunization Rates of Patients with Chronic Kidney Disease Including Dialys
Release Date:
Review Process: Pfizer Internal
Education Hospital Albania
Integrated Approach to Breast Health Equity
Release Date:
Review Process:
Patient Registries In Metastatic Breast Cancer
Release Date:
Review Process:
Improving Patient Care in Tobacco Dependency
Release Date:
Review Process:
Antimicrobial Stewardship in the Latin America Region
Release Date:
Review Process:
Management of Atopic Dermatitis – International Developed Markets
Release Date:
Review Process:
Improving Standard of Care for Chronic AD
Release Date:
Review Process:
NCCN and Pfizer: Enhancing Academic-Community-Patient Partnerships in Metastatic Breast Cancer Care
Release Date:
Review Process:
Translating the Atopic Dermatitis (AD)
Release Date:
Review Process:
UK Oncology Quality Improvement Grants
Release Date:
Review Process: